Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 5/20 | 0.63 |
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | PPARG | P37231 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416652 | 0.89 | PPARD (0.68) | PPARDPPARAPPARGHTTMCHR1 | |
| SCHEMBL13460925 | 0.85 | PPARG (0.60) | PPARDPPARAPPARGHTTMCHR1 | |
| SCHEMBL5032986 | 0.78 | PPARA (0.68) | PPARDPPARAPPARGMCHR1TRPV1 | |
| SCHEMBL6502631 | 0.76 | PPARA (0.75) | PPARDPPARAPPARG | |
| SCHEMBL3418889 | 0.76 | PPARG (0.45) | PPARDPPARAPPARGHTTEPHX2 | |
| SCHEMBL6504915 | 0.75 | PPARG (0.75) | PPARDPPARAPPARG | |
| SCHEMBL6426198 | 0.74 | PPARA (0.62) | PPARDPPARAPPARGMCHR1MEN1 | |
| SCHEMBL5032977 | 0.73 | PPARA (0.61) | PPARDPPARAPPARGMCHR1TRPV1 | |
| SCHEMBL3416041 | 0.72 | LMNA (0.50) | PPARDPPARAPPARG | |
| SCHEMBL3418634 | 0.71 | PPARD (0.69) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | PPARD 689/4885PPARA 130/4885PPARG 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.